1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF SAUDI ARABIA Q-PCR REAGENTS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCTS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 GLOBAL QPCR REAGENTS MARKET, PRICING ANALYSIS
5 COST ANALYSIS BREAKDOWN
6 HEALTHCARE ECONOMY
7 INDUSTRY INSIGHTS
8 INNOVATION TRACKER AND STRATEGIC ANALYSIS
9 TECHNOLOGY ROADMAP
10 VALUE CHAIN ANALYSIS
11 REGULATIONS
12 MARKET OVERVIEW
12.1 DRIVERS
12.1.1 INCREASING PREVALENCE OF CHRONIC AND COMMUNICABLE DISEASES
12.1.2 INCREASE IN GERIATRIC POPULATION
12.1.3 INCREASE IN EARLY DIAGNOSIS RATE
12.1.4 INCREASE IN ADVANCED TECHNOLOGY
12.2 RESTRAINTS
12.2.1 STRINGENT RULES AND REGULATIONS
12.2.2 HIGH COST OF PRODUCT
12.3 OPPORTUNITIES
12.3.1 RISE IN GOVERNMENT FUNDING FOR HEALTHCARE
12.3.2 RISE IN HEALTHCARE EXPENDITURE
12.4 CHALLENGES
12.4.1 LACK OF SKILLED WORKFORCE
12.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS
13 SAUDI ARABIA QPCR REAGENTS MARKET, BY TYPE
13.1 OVERVIEW
13.2 REAGENTS
13.2.1 MASTER MIX
13.2.1.1 DNA
13.2.1.2 RNA
13.2.2 PRIMERS AND DNTPS
13.2.3 ASSAY
13.2.4 NUCLEIC ACID GEL STAIN
13.2.5 DNASE BUFFER
13.2.6 OTHERS
13.2. CONSUMABLES
13.2.1. PIPETTE TIPS
13.2.2. TUBES
13.2.3. PLATES
13.2.3.1. STANDARD
13.2.3.2. CUSTOM
13.2.4. SEALING FOILS
13.2.5. TUBE STRIPS
13.2.6. OTHERS
14 SAUDI ARABIA QPCR REAGENTS MARKET, BY APPLICATION
14.2. OVERVIEW
14.3. CLINICAL
13.3 HUMAN DIAGNOSTICS
14.3.1.1. HOSPITALS
14.3.1.2. DIAGNOSTIC CENTERS
14.3.1.3. PATHOLOGY LABS
14.3.1.4. OTHERS
13.4 VETERINARY DIAGNOSTICS
14.3.1.5. VETERINARY HOSPITALS
14.3.1.6. DIAGNOSTIC CENTERS
14.3.1.7. VETERINARY LABORATORY
14.3.1.8. VETERINARY CLINICS
14.4. RESEARCH
14.4.1. GENE EXPRESSION ANALYSIS
14.4.1.1. RESEARCH & ACADEMIC INSTITUTES
14.4.1.2. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.4.1.3. OTHERS
14.4.2. GENOTYPING
14.4.2.1. RESEARCH & ACADEMIC INSTITUTES
14.4.2.2. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.4.2.3. OTHERS
14.4.3. MICROBE AND PATHOGEN DETECTION
14.4.3.1. RESEARCH & ACADEMIC INSTITUTES
14.4.3.2. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.4.3.3. OTHERS
14.4.4. SINGLE NUCLEOTIDE POLYMORPHISM (SNP) DETECTION
14.4.4.1. RESEARCH & ACADEMIC INSTITUTES
14.4.4.2. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.4.4.3. OTHERS
14.4.5. DRUG DEVELOPMENT
14.4.5.1. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.4.5.2. CLINICAL RESEARCH ORGANIZATION
14.4.5.3. RESEARCH & ACADEMIC INSTITUTES
14.4.5.4. OTHERS
14.4.6. DRUG DISCOVERY
14.4.6.1. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.4.6.2. CLINICAL RESEARCH ORGANIZATION
14.4.6.3. RESEARCH & ACADEMIC INSTITUTES
14.4.6.4. OTHERS
14.4.7. OTHERS
14.5. FOOD PRODUCT SAFETY TESTING
14.5.1. FOOD REGULATORY AGENCIES
14.5.2. FOOD TESTING LABORATORIES
14.5.3. FOOD COMPANIES
14.5.4. OTHERS
14.6. FORENSICS
14.6.1. PRIVATE FORENSIC LABORATORIES
14.6.2. PUBLIC FORENSIC LABORATORIES
14.7. OTHERS
15 SAUDI ARABIA QPCR REAGENTS MARKET, BY END USER
15.2. OVERVIEW
15.3. HOSPITALS
15.4. DIAGNOSTIC CENTERS
15.5. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
15.6. RESEARCH & ACADEMIC INSTITUTE
15.7. CLINICAL RESEARCH ORGANIZATION
15.8. VETERINARY LABS
15.9. FORENSIC LABORATORIES
15.10. OTHERS
16 SAUDI ARABIA QPCR REAGENTS MARKET, BY DISTRIBUTION CHANNEL
16.2. OVERVIEW
16.3. DIRECT TENDER
16.4. RETAIL SALES
16.5. OTHERS
17 SAUDI ARABIA QPCR REAGENTS MARKET: COMPANY LANDSCAPE
17.2. COMPANY SHARE ANALYSIS: SAUDI ARABIA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.2. F. HOFFMANN-LA ROCHE LTD
19.2.1. COMPANY SNAPSHOT
19.2.2. REVENUE ANALYSIS
19.2.3. PRODUCT PORTFOLIO
19.2.4. RECENT DEVELOPMENT
19.3. THERMO FISHER SCIENTIFIC INC.
19.3.1. COMPANY SNAPSHOT
19.3.2. REVENUE ANALYSIS
19.3.3. PRODUCT PORTFOLIO
19.3.4. RECENT DEVELOPMENTS
19.4. AGILENT TECHNOLOGIES, INC.
19.4.1. COMPANY SNAPSHOT
19.4.2. REVENUE ANALYSIS
19.4.3. PRODUCT PORTFOLIO
19.4.4. RECENT DEVELOPMENTS
19.4.4.1. DISTRIBUTION AGREEMENT
19.4.4.2. PRODUCT LAUNCH
19.5. BIO-RAD LABORATORIES, INC.
19.5.1. COMPANY SNAPSHOT
19.5.2. REVENUE ANALYSIS
19.5.3. PRODUCT PORTFOLIO
19.5.4. RECENT DEVELOPMENTS
19.6. QUANTABIO
19.6.1. COMPANY SNAPSHOT
19.6.2. PRODUCT PORTFOLIO
19.6.3. RECENT DEVELOPMENT
19.7. ENZO BIOCHEM INC
19.7.1. COMPANY SNAPSHOT
19.7.2. REVENUE ANALYSIS
19.7.3. PRODUCT PORTFOLIO
19.7.4. RECENT DEVELOPMENT
19.8. MERIDIAN BIOSCIENCE
19.8.1. COMPANY SNAPSHOT
19.8.2. PRODUCT PORTFOLIO
19.8.3. RECENT DEVELOPMENTS
19.9. NORGEN BIOTEK CORP
19.9.1. COMPANY SNAPSHOT
19.9.2. PRODUCT PORTFOLIO
19.9.3. RECENT DEVELOPMENT
19.10. QIAGEN
19.10.1. COMPANY SNAPSHOT
19.10.2. REVENUE ANALYSIS
19.10.3. PRODUCT PORTFOLIO
19.10.4. RECENT DEVELOPMENTS
19.11. SINO BIOLOGICAL INC.
19.11.1. COMPANY SNAPSHOT
19.11.2. PRODUCT PORTFOLIO
19.11.3. RECENT DEVELOPMENT
19.12. TAKARA HOLDINGS INC
19.12.1. COMPANY SNAPSHOT
19.12.2. REVENUE ANALYSIS
19.12.3. PRODUCT PORTFOLIO
19.12.4. RECENT DEVELOPMENTS
19.13. TONBO BIOSCIENCES (A SUBSIDIARY OF CYTEK BIOSCIENCES)
19.13.1. COMPANY SNAPSHOT
19.13.2. PRODUCT PORTFOLIO
19.13.3. RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS